Journal Title
Immunotherapy

IMMUNOTHERAPY-UK

ISSN / eISSN
1750-743X / 1750-7448
Aims and Scope
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.

Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
Subject Area

IMMUNOLOGY

CiteScore
6.00 View Trend
CiteScore Ranking
Category Quartile Rank
Medicine - Oncology Q2 #128/366
Medicine - Immunology and Allergy Q2 #93/211
Medicine - Immunology Q3 #113/217
Web of Science Core Collection
Science Citation Index Expanded (SCIE) Social Sciences Citation Index (SSCI)
Indexed -
Category (Journal Citation Reports 2023) Quartile
IMMUNOLOGY - SCIE Q4
H-index
37
Country/Area of Publication
ENGLAND
Publisher
Future Medicine Ltd.
Publication Frequency
Bimonthly
Annual Article Volume
101
Open Access
NO
Contact
FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started